Clinical trial
Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem…
NCT00003966 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003966 |
|---|---|
| Title | Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell Transplantation |
| Official title | Defibrotide for Hematopoietic Stem Cell Transplant Patients With Severe Hepatic Venocclusive Disease: A Phase I/II Study to Determine the Minimal Effective Dose |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Jazz Pharmaceuticals Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Veno-occlusive Disease |
| Intervention type | Drug |
| Interventions | defibrotide |
| Enrollment | 151 |
| Start date | Apr 1, 2000 |
| Primary completion | Feb 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: